RVNC

Revance Therapeutics, Inc.

7.14 USD
+1.48 (+26.15%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Revance Therapeutics, Inc. stock is up 29.58% since 30 days ago. The next earnings date is May 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 10 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 6 PUTs, 4 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
10 Jan 16:56 19 Jan, 2024 7.50 PUT 750 6154
11 Jan 16:52 17 Jan, 2025 7.50 CALL 150 2945
12 Jan 20:42 19 Apr, 2024 20.00 PUT 99 0
12 Jan 20:43 19 Jan, 2024 20.00 PUT 51 2080
16 Jan 17:41 17 Jan, 2025 7.50 CALL 150 3095
25 Jan 17:30 19 Jul, 2024 5.00 CALL 232 130
30 Jan 15:00 19 Jul, 2024 5.00 CALL 168 427
31 Jan 20:59 19 Apr, 2024 10.00 PUT 50 67
06 Feb 18:39 17 Jan, 2025 12.50 PUT 40 141
29 Feb 15:19 17 Jan, 2025 12.50 PUT 40 181

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia.

  • Piper Sandler
    Thu Feb 29, 08:42
    buy
    confirm
  • Needham
    Thu Feb 29, 08:32
    buy
    confirm
  • HC Wainwright & Co.
    Fri Feb 23, 09:30
    buy
    confirm